Screening assays
First Claim
Patent Images
1. A method of screening for compounds that reduce and/or prevent obesity comprising a) contacting a cell expressing a gene selected from the group consisting of Seq. ID Nos. 1-6 with a compound;
- b) measuring the expression of said gene, or the expression of a polypeptide encoded by said gene; and
c) determining whether the compound up-regulates the expression of said gene or of the polypeptide encoded by said gene.
2 Assignments
0 Petitions
Accused Products
Abstract
The present invention relates to novel gene and polypeptide targets identified in skeletal muscle for screening of compounds that may be useful for the prevention and treatment of obesity.
10 Citations
24 Claims
-
1. A method of screening for compounds that reduce and/or prevent obesity comprising
a) contacting a cell expressing a gene selected from the group consisting of Seq. ID Nos. 1-6 with a compound; -
b) measuring the expression of said gene, or the expression of a polypeptide encoded by said gene; and
c) determining whether the compound up-regulates the expression of said gene or of the polypeptide encoded by said gene. - View Dependent Claims (2, 3, 4, 5, 6, 7)
-
-
8. A method of screening for compounds that reduce and/or prevent obesity comprising
a) contacting a cell expressing a gene selected from the group consisting of Seq. ID Nos. 7 and 8 with a compound; -
b) measuring the expression of said gene, or the expression of a polypeptide encoded by said gene;
c) determining whether the compound down-regulates the expression of said gene or of activity of a polypeptide encoded by said gene. - View Dependent Claims (9, 10)
-
-
11. A method of screening for compounds that reduce and/or prevent obesity comprising
a) contacting a cell expressing a gene selected from the group consisting of Seq ID No. 17 to 27 with a compound; -
b) measuring the expression of said gene, or the expression of a polypeptide encoded by said gene; and
c) determining whether the compound up-regulates the expression of said gene or of the polypeptide encoded by said gene.
-
-
12. A method of screening for compounds that reduce and/or prevent obesity comprising
a) contacting a cell expressing a gene selected from the group consisting of Seq ID No. 28 to 43 with a compound; -
b) measuring the expression of said gene, or the expression of a polypeptide encoded by said gene; and
c) determining whether the compound down-regulates the expression of said gene or of a polypeptide encoded by said gene.
-
-
13. A method of screening for compounds that reduce and/or prevent obesity comprising:
-
a) contacting a polypeptide selected from the group consisting of Seq ID No. 9 to 14 with a compound; and
b) determining the activity of said polypeptide relative to the activity of such polypeptide in the absence of such compound;
wherein a compound which reduces and/or prevents obesity by agonizing said polypeptide is a compound which causes an increase in activity of said polypeptide.
-
-
14. A method of screening for compounds that reduce and/or prevent obesity comprising:
- a) contacting a polypeptide selected from the group consisting of Seq ID No. 15 to 16 with a compound; and
b) determining the activity of said polypeptide relative to the activity of such polypeptide in the absence of such compound;
wherein a compound which reduces and/or prevents obesity by antagonizing said polypeptide is a compound which causes a decrease in activity of said polypeptide.
- a) contacting a polypeptide selected from the group consisting of Seq ID No. 15 to 16 with a compound; and
-
15. A method of screening for compounds that reduce and/or prevent obesity comprising:
-
a) contacting a polypeptide selected from the group consisting of Seq ID No. 44 to 54 with a compound; and
b) determining the activity of said polypeptide relative to the activity of such polypeptide in the absence of such compound;
wherein a compound which reduces and/or prevents obesity by agonizing said polypeptide is a compound which causes an increase in activity of said polypeptide.
-
-
16. A method of screening for compounds that reduce and/or prevent obesity comprising:
- a) contacting a polypeptide selected from the group consisting of Seq ID No. 55 to 70 with a compound; and
b) determining the activity of said polypeptide relative to the activity of such polypeptide in the absence of such compound;
wherein a compound which reduces and/or prevents obesity by antagonizing said polypeptide is a compound which causes a decrease in activity of said polypeptide.
- a) contacting a polypeptide selected from the group consisting of Seq ID No. 55 to 70 with a compound; and
-
17. A method for screening of compounds that reduce and/or prevent obesity comprising:
- a) contacting a cell expressing a nucleic acid encoding a polypeptide selected from the group consisting of Seq ID No. 9 to 14 with a compound; and
b) determining the activity of said polypeptide relative to the activity of such polypeptide in the absence of such compound;
wherein a compound which reduces and/or prevents obesity by agonizing said polypeptide is a compound which causes an increase in activity of said polypeptide.
- a) contacting a cell expressing a nucleic acid encoding a polypeptide selected from the group consisting of Seq ID No. 9 to 14 with a compound; and
-
18. A method for screening of compounds that reduce and/or prevent obesity comprising:
- a) contacting a cell expressing a nucleic acid encoding a polypeptide selected from the group consisting of Seq ID No. 15 and/or 16 with a compound; and
b) determining the activity of said polypeptide relative to the activity of such polypeptide in the absence of such compound;
wherein a compound which reduces and/or prevents obesity by antagonizing said polypeptide is a compound which causes a decrease in activity of said polypeptide.
- a) contacting a cell expressing a nucleic acid encoding a polypeptide selected from the group consisting of Seq ID No. 15 and/or 16 with a compound; and
-
19. A method for screening of compounds that reduce and/or prevent obesity comprising:
- a) contacting a cell expressing a nucleic acid encoding a polypeptide selected from the group consisting of Seq ID No. 44 to 54 with a compound; and
b) determining the activity of said polypeptide relative to the activity of such polypeptide in the absence of such compound;
wherein a compound which reduces and/or prevents obesity by agonizing said polypeptide is a compound which causes an increase in activity of said polypeptide.
- a) contacting a cell expressing a nucleic acid encoding a polypeptide selected from the group consisting of Seq ID No. 44 to 54 with a compound; and
-
20. A method for screening of compounds that reduce and/or prevent obesity comprising:
- a) contacting a cell expressing a nucleic acid encoding a polypeptide selected from the group consisting of Seq ID No. 55 to 70 with a compound; and
b) determining the activity of said polypeptide relative to the activity of such polypeptide in the absence of such compound;
wherein a compound which reduces and/or prevents obesity by antagonizing said polypeptide is a compound which causes a decrease in activity of said polypeptide.
- a) contacting a cell expressing a nucleic acid encoding a polypeptide selected from the group consisting of Seq ID No. 55 to 70 with a compound; and
-
21. A method of screening for compounds that bind to a polypeptide selected from the group consisting of the polypeptides of Seq ID No. 9 to 16, comprising the steps of
a) contacting a compound with said polypeptide; - and
b) determining the ability of said compound to bind to said polypeptide.
- and
-
22. A method of screening for compounds that bind to a polypeptide selected from the group consisting of the polypeptides of Seq ID No. 44 to 70, comprising the steps of
a) contacting a compound with said polypeptide; - and
b) determining the ability of said compound to bind to said polypeptide.
- and
-
23. A pharmaceutical composition for the modulation of body weight, comprising a compound that modulates the expression or activity of a polypeptide selected from the group consisting of Seq ID No. 9 to 16, mixed with a pharmaceutically acceptable carrier.
-
24. A pharmaceutical composition for the modulation of body weight, comprising a compound that modulates the expression or activity of a polypeptide selected from the group consisting of Seq ID No 44 to 70, mixed with a pharmaceutically acceptable carrier.
Specification